ISTODAX included in the updated NCCN Clinical Practice Guidelines in Oncology

Dec 4 2009

Gloucester Pharmaceuticals announced today that ISTODAX^® (romidepsin) has been included in the updated National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology™ as a suggested systemic treatment option for patients with mycosis fungoides and Sézary syndrome—two of the most common types of cutaneous T-cell lymphoma (CTCL). ISTODAX, a member of a new class of cancer drugs known as histone deacetylase (HDAC) inhibitors, received FDA approval in early November for the treatment of CTCL in patients who have received at least one prior systemic therapy.

"The inclusion of ISTODAX in the NCCN Guidelines is an important step forward in potentially improving clinical outcomes for patients with CTCL who have received prior systemic therapy," said Alan Colowick, MD, Chief Executive Officer of Gloucester Pharmaceuticals. “Physicians and their patients need treatment options that can offer sustained improvement in their disease. We expect that ISTODAX will be available in January 2010 and look forward to providing a much needed addition to the treatment armamentarium for CTCL."